Clinical Neuroscience

[THE SELECTIVE COX-2 INHIBITOR MELOXICAM AND SALICYLATE THERAPY]

TÓTH Károly

MAY 10, 2005

Clinical Neuroscience - 2005;58(05-06)

[Although during treatment of arthrosis with meloxicam the level of thromboxan A2 decreases, thrombocyte functions are not affected. Meloxicam in therapeutic doses doesn’t increase the risk of haemorrhage. Previously it was suspected that coadministration of salicylates with certain other non-steroid antiinflammatory drugs (NSAIDs) will suppress the effect of salicylate. Van Ryn et al have proved that this is not the case with salicylate plus meloxicam therapy. It is hypothesized that meloxicam loosely binds to the cyclooxygenase-1 (COX-1) enzyme and salicylate can easily replace it.]

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[Testing the administration of cannabinoids in neurological diseases]

Clinical Neuroscience

[Ferenc Obál Jr.]

BENEDEK György

Clinical Neuroscience

[CONGRESS CALENDAR]

Clinical Neuroscience

[Frontotemporal dementia - Part I History, prevalence, clinical forms]

GALARIOTIS Vasilis, BÓDI Nikoletta, JANKA Zoltán, KÁLMÁN János

[The authors report a comprehensive publication consisting of three parts going into the details of history, prevalence, clinical forms, differential diagnosis, genetics, molecular pathomechanism, pathology, clinical diagnosis and treatment of frontotemporal dementia (FTD). The first part of the present review deals with history, prevalence and clinical forms of FTD. The prototypical FTD with circumscribed atrophy was first described by Arnold Pick; Alois Alzheimer found the intraneural inclusions in the patients’ brain. Later it was recognised that many patients had neither the atrophy nor the cellular changes, but genetic mutations have been identified. Frontotemporal dementia is a degenerative condition with unknown etiology in the frontal and anterior temporal lobes of the brain. It is a progressive neurobehavioral syndrome characterized by early decline in social interpersonal conduct, early impairment in the regulation of personal conduct, early emotional blunting, and early loss of insight. There are no reliable epidemiological studies on the prevalence of FTD, but it is well-accepted that FTD is a common cause for dementia before the age of 65 (it constitues approximately five percent of all irreversible dementias). The nomenclature of the FTD has been confusing and continues to be. Three major clinical syndromes can be identified: 1 frontal variant FTD (dementia of frontal type) in which changes in social behavior and personality predominate, 2. in semantic dementia (progressive fluent aphasia) there is a breakdown in the conceptual database which underlies language production and comprehension, 3. in progressive nonfluent aphasia the phonologic and syntactic components of language are affected. The authors report two cases, which can point to clinical symptoms and forms, and mention the problems of the differential diagnosis and therapy.]

Clinical Neuroscience

[A case history and diagnostical rewiev of primary cerebral angiitis]

CSÉPÁNY Tünde, KOLLÁR József, SIKULA Judit, MOLNÁR Mária, CSIBA László

[The authors present a case history of primary cerebral angiitis with four years of follow-up. The early diagnosis was based on typical clinical symptoms, brain MRI, intracerebral MRA and histology of sural nerve biopsy. Electroneurography suggested peripheral involvement, although the patient did not have clinical signs of peripheral neuropathy. Glucocorticoid and immunosuppressive treatment resulted in remission. The diagnostic difficulties of primary cerebral vasculitis are also summarized in the discussion.]

All articles in the issue

Related contents

Lege Artis Medicinae

[ROLE OF TISSUE ANGIOTENSIN CONVERTING ENZYME IN CARDIOVASCULAR DISEASES]

MOHÁCSI Attila, LIZANECZ Erzsébet, ÉDES István, CZURIGA István

[The pathobiological aim of treatment with angiotensin converting enzyme inhibitor is to restore the balance between nitrogen-monoxide and angiotensin II due to inhibition of blood and tissue angiotensin converting enzyme. The clinical consquences of the inhibition of tissue angiotensin converting enzyme in patients with additionally high (HOPE) and low (EUROPA) cardiovascular risk without left ventricular dysfunction has already been demonstrated. Ramipril and the perindopril reduce the risk of combined end-point of these trials such as cardiovascular mortality, reinfarction and resuscitated sudden cardiac death. However, pharmacological and genetic differences in blocking of tissue angiotensin converting enzyme may influence the cardioprotective effect of various angiotensin converting enzyme inhibitors. Thus new, well-designed, controlled clinical trials are needed to determine the role of angiotensin converting enzyme inhibitor with different tissue angiotensin converting enzyme affinity in cardiovascular disease.]

Lege Artis Medicinae

[Is postmenopausal hormone therapy suitable for cardiovascular prevention?]

LÁSZLÓ Ádám

[After menopause, coronary disease and infarction become increasingly common in women owing to estrogen deficiency. Therefore, hormon replacement therapy (HRT) had been widely used to prevent these problems and manage postmenopausal symptoms. In 2002, a large, randomised, placebo-controlled study reported that HRT was accompanied by serious side effects and was not suitable for cardiovascular prevention. However, subsequent re-alanyses of the data of this study and new studies in the past 10 years suggest that in women younger than 60 years and if started within 10 years after the menopause, HRT has a number of advantages and very few disadvantages. It substantially improves quality of life, while the absolute risk of side effects is small, and HRT is suitable for the primary prevention of coronary diseases. I summarise the cardiovascular aspects of menopausal hormone therapy, in order to help the necessary paradigm shift in this matter.]

Lege Artis Medicinae

[The drug-treatment of atherosclerosis by statins]

KÉKES Ede

[The pathogenesis of atherosclerosis is a complex and complicated process. The rule of some factors (lipoproteindeposition, oxidative stress, lipid peroxidation, endothel dysfunction, etc) is well known, but others are not yet clarified. Conventional, metabolic and some special residual factors have also influenced for the starting process. One of them, the lipid profile is the most important. Statins are able to decrease the lipid levels - LDL cholesterol - significantly to the physiological level. These drugs are essential for the primer and secunder cardiovascular prevention moreover it is advisable to give in acute coronary syndrome as well. The most excellent statin is rosuvastatin, because of beneficial effect to decreasing LDL cholesterol level and cardiovascular events. Rosuvastatin is able to produce a regression of atherosclerotic process int he vessel walls. Presumably this effect can be explained by their pleiotrop property.]

Lege Artis Medicinae

[Cardiovascular screening and risk stratification]

VÉRTES András

[Cardiovascular diseases are still leading cause of death in developed countries. A possible background, atherosclerosis, might appear even in childhood, and deteriorate during the years without any symptoms. The cardiovascular prevention is a complex activity, which can be observed in population or/and in individual level. The conventional screening means the assessment of higher cholesterol level, blood pressure or other risk factors in healthy population without symptoms. The point of clinical risk evaluation is to find patient with high cardiovascular risk and consequentially with the necessity of intensive preventive strategy. For the right cardiovascular screening and adequate evaluation of the risk, it is needed that the doctors who frequently meet with the population execute the above-mentioned risk assessment. Therefore doctors, nurses, and education for preventive aspect would is needed, as education is important to decrease cardiovascular mortality for those patients that were categorized as a high-risk group.]

Lege Artis Medicinae

[Occurrence of cardiometabolic risk factors among shift workers]

JERMENDY György, NÁDASI Judit, HEGYI Ilona, VASAS István, HIDVÉGI Tibor

[INTRODUCTION - Shift workers have an impaired circadian rhythm, which might have an adverse effect on their health. In order to assess cardiometabolic risk in shift workers, a cross-sectional study was performed among active workers (aged 25-66 years, with a minimal shift working experience of 5 years). METHODS - In total 481 workers (121 men, 360 women) registered by the occupational health service were enrolled in our study. Most participants worked in the light industry (58.2%) or in public service (23.9%). Following questionnaire-based data recording, anthropometric measurements and physical examination were performed and fasting venous blood sample was taken for measuring laboratory parameters. Data from shift workers (n=234, 54 men and 180 women, age: 43.9±8.1 years) were compared with those of day workers (n=247, 67 men and 180 women, age: 42.8±8.5 years). RESULTS - Compared with day workers, shift workers had bigger weight (76.6±16.1 vs 73.9±17.6 kg; p<0.05), higher BMI index (27.5±5.3 vs 26.0±4.9 kg/m2; p<0.01) and systolic blood pressure (123±19 vs 119±16 mmHg, p<0.01), and higher prevalence rate of diabetes (4.3 vs 1.2 %; p<0.05) and cardiovascular diseases (3.8 vs 0.8 %; p<0.05). In addition, the proportion of participants who performed regular physical activity was lower (20.6 vs 38.7 %; p<0.001) and that of current smokers were higher (35.0 % vs 19.5 %; p<0.001) in shift workers than in day workers. In laboratory findings, only one difference has been found: HDL-cholesterol level was lower among women (shift workers versus workers: 1.56±0.32 vs 1.68±0.36 mmol/l; p<0.01). CONCLUSION - Long-term shift work (day-night) results in a less healthy lifestyle and worse cardiometabolic risk factors compared with day work. Thus, our study highlights the importance of measures for preventing cardiovascular diseases in shift workers.]